期刊文献+

高通量血液透析临床疗效的综合分析 被引量:5

Comprehensive evaluation of high flux hemodialysis
原文传递
导出
摘要 目的了解高通量透析对维持性血液透析患者实验室检查指标及生活质量的影响。方法选取32例维持性血液透析患者,将每2周1次血液透析滤过、1次血液灌流,其余时间进行低通量透析的模改为每周3次高通量透析,进行为期6个月的观察。前3个月使用旭化成13u透析器,后3个月使用旭化成15u透析器,分别在使用前和使用后3个月、6个月监测患者血压、血红蛋白、血白蛋白、前白蛋白、钙、磷、维生素D、全片段甲状旁腺激素、β2-微球蛋白、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、脂蛋白a水平的变化,同时应用简明健康测量量表、匹兹堡睡眠量表、食欲量表调查评价患者的生活质量。结果(1)患者收缩压、舒张压均显著下降(P〈0.05),换用15u透析器治疗3个月后,收缩压、舒张压继续下降(P〈0.05)。(2)治疗3个月后患者血红蛋白、白蛋白、前白蛋白、p2一微球蛋白及超敏C反应蛋白未见明显变化,换用15u透析器治疗3个月后,白蛋白及前白蛋白显著上升,132一微球蛋白显著下降(P〈0.05)。(3)治疗3个月后患者钙、磷、全段甲状旁腺素及维生素D均无明显变化;换用15u透析器治疗3个月后,维生素D显著下降(P〈0.05),部分患者骨痛改善。(4)治疗3个月后患者血清低密度脂蛋白显著下降(P〈0.05),其余指标无明显变化;换用15u透析器治疗3个月后,患者血清低密度脂蛋白继续下降(P〈0.05),血清高密度脂蛋白水平升高,载脂蛋白A1水平下降(P〈0.05)。(5)治疗6个月后,患者总体生活质量变化不显著,食欲和睡眠状况有改善趋势,但差别未见统计学意义。结论规律高通量透析对临床及实验室检查指标的改善作用明显优于每周或每2周1次血液透析滤过,其余时间进行低通量透析的组合模式,特别是在血压控制、营养状态的改善及脂代谢指标等方面。 Objectives To evaluate the influence of high - flux hemodialysis to the result of laboratory examination and quality of life. Methods Thirty - two patients of maintenance hemodialysis who received hemodia- fltration and hemoperfusion every other week with low - flux hemodialysis in other time were converted to regular high -flux hemodialysis three times a week. The observation were continued for six months, in the first three months of which Asahi 13u dialyzer were used and Asahi 15u dialyzer were used in the remaining three months. Blood pres- sure, hemoglobin, albumin, prealbumin, calcium, phosphorus, vitamine D, intact parathyroid hormone, 132 - mi- croglobulin, cholesterol, triglyceride, high - density lipoprotein, low - density lipoprotein, apolipoprotein - A1 and B2 were evaluated in every changing point. Meanwhile, short form 36 health survey questionnaire, Pittsburgh sleep quality index and appetide questionnaire were used to evaluate the life quality of the patients. Results ( 1 ) Sys- tolic pressure and diastolic pressure were significantly declined ( P 〈 0.05 ) in the first three months. After three months use of 15u dialyzer, blood pressure still decline( P 〈0.05 ). (2)Hemoglobin, albumin, prealbumin, β2 - microglobulin and hypersensitive C - reactive protein did not change in the first three months. After three months use of 15u dialyzer, albumin and prealbumin increased, while β2 -micmglobulin decreased significantly( P 〈0.05 ). ( 3 ) Calcium, phosphorus, vitamine D and intact parathyroid hormone did not change in the first three months. After three months use of 15u dialyzer, vitamine D declined significantly( P 〈 O. 05 ). Bone pain of some patients less- ened. (4) Low - density lipoprotein declined siguificantly in the first three months ( P 〈 O. 05 ). After three months use of 15 u dialyzer, low - density lipoprotein continued to decline ( P 〈 O. 05 ), while high - density lipoprotein and apolipoprotein A1 declined significantly ( P 〈 0.05 ). (5)Significant change of life quality did not occur during the observation. Appetite and quality of sleep intended to get better, but statistically significant change can not be detec- ted. Conclusions After three months use of Asahi 13u high -flux dialyzer, systolic pressure, diastolic pressure and low - density lipoprotein declined significantly. After three months use of Asahi 15u high - flux dialyzer, systolic pressure, diastolic pressure and low - density lipoprotein continued to decline. Albumin, prealbumin and high - density lipoprotein increased, while β2 -microglobulin, apolipoprotein A1 and vitamine D declined significantly.
出处 《国际泌尿系统杂志》 2012年第6期726-732,共7页 International Journal of Urology and Nephrology
关键词 血液透析 Hemodialysis
  • 相关文献

参考文献27

  • 1左力.高通量透析改善维持性血液透析患者的预后[J].中国血液净化,2010,9(1):6-11. 被引量:33
  • 2Eknoyan G,Beck GJ, Cheung AK, et al. Effect of dialysis doseand membrane flux in maintenance hemodialysis. N Engl J Med,2002,347:2010-2019.
  • 3Leypoldt JK. Solute fluxes in different treatment modalities. Neph-rol Dial Transpaint,2000, 15( Suppl 1) : S3 -9.
  • 4Qureshi AR, Alvestrand A, Divino - Filho JC, et al. Inflamma-tion ,malnutrition,and cardiac disease as predictors of mortality inhemodialysis patients. J Am Soc Nephrol,2002,13 Suppl 1 :S28 -36.
  • 5Li PK, Cheng YL, Leung CB, et al. Effect of membrane permea-bility on inflammation and arterial stiffness : a randomized trial.Clin J Am Soc Nephrol,2010,5:652 -658.
  • 6Marcus RG, Cohl E, Uribarri J. Middle molecule clearance doesnot influence protein intake in hemodialysis patients. Am J KidneyDis, 1998,31: 491 -494.
  • 7徐丰博,刘惠兰,左力,吴华,李冀军,蔡砺,汤天清,殷培,程叙扬,鲍云飞.高通量血液透析对患者营养状况的临床观察[J].中国血液净化,2010,9(12):662-664. 被引量:13
  • 8Locatelli F, Martin - Malo A, Hannedouche T, et al. Effect ofmembrane permeability on survival of hemodialysis patients. J AmSoc Nephrol,2009,20: 645 -654.
  • 9Harper CR,Jacobson TA. Managing dyslipidemia in chronic kid-ney disease. J Am Coll Cardiol ,2008,51 : 2375 -2384.
  • 10Cheung AK. Is lipid control necessary in hemodialysis patients. Clin J Am Soc Nephrol,2009,Suppl 1 : S95 - 101.

二级参考文献89

  • 1季大玺.高通量血液透析的新认识[J].中国中西医结合肾病杂志,2005,6(10):559-562. 被引量:13
  • 2黄文坛,丁国华,龚智峰.高通量血液透析对尿毒症患者瘦素清除效果的临床研究[J].内科,2007,2(3):313-315. 被引量:5
  • 3Blankestijn PJ, Vos PF, Rabelink TJ, et al. High-flux dialysis membranes impcove lipid profile in chronic hemodialysis patients[J]. J Am Soc Nephrol, 1995, 5: 1703- 1708.
  • 4Wanner C, gahner U, Mattern R, et al. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemndialysis patients[J]. Nephvol Dial Transplant, 2004, 19:2570 -2575.
  • 5Goldberg IJ, Kaufman AM, Lavarias VA, et al. High flux dialysis membranes improve plasma lipoprotein profiles in patients wilh end sl;age renal disease[J].Nephrol Dial Transplant, 1996, 11 (Suppl 2): 104--107.
  • 6Blankestijn PJ. Hemodialysis using high flux membranes improves lipid profiles. Clin Nephrol, 1994, 42 Suppl 1: S48-51.
  • 7Moshfegh A, Jacobson SH, llallden G, et al. Impact of hemodialysis membrane and permeability on neutrophil transmigration in vitro[J]. Nephron, 2002, 91: 659-665.
  • 8Chu PL, Chiu YL,Lin .JW, et al. Effects of low- and high flux dialyzers on oxidative stress and insulin resistance[J]. Blood Purif, 2008, 26:213 -220.
  • 9Ramirez R, Carracedo J, Merino A, et el. Microinflammation induces endothelial damage in hemodialysis patients: the role of convective transport[J]. Kidney Int, 2007, 72: 108- 113.
  • 10Merino A, Nogueras S, Buendia P, et al. Microinflammation and endothelial damage in hemodialysis[J]. Contrib Nephrol, 2008, 161:83 -88.

共引文献81

同被引文献48

  • 1Shlipak MG. Mattes MD. Peralta CA. Update on cystatin c , incorporation into clinical practice[J]. Am J Kidney Dis. 2013. 62(3): 595-603.
  • 2Harman G. Akbari A. Hiremath Sv et al. Accuracy of cystatin cbased estimates of glomerular filtration rate in kidney transplant recipients: a systematic review [J]. Nephrol Dial Transplant. 2013.28(3) : 741-757.
  • 3Breitsameter G. Figueiredo AE. Kochhann DS. Calculation of kt/v in haernodialysis s a comparison between the formulas[J]. J Bras Nefrol,2012.34(1) :22-26.
  • 4Diaz-Buxo JA. Loredo JP. Standard kt/v , comparison of calculation methods[J]. Artif Organs. 2006. 30( 3) : 178-185.
  • 5Casino FG.Pedrini LA. Santoro A.et al. A simple approach for assessing equilibrated kt/v beta 2-M on a routine basis [J]. Nephrol Dial Transplant.2010.25(9) :3038-3044.
  • 6Ledebo 1. Development of hemodiafiltration therapy=a historical perspective[J]. Blood Purif , 2013. 35(Suppl 1) : 6-10.
  • 7Gejyo F. Amana 1, Ando T, et al. Survey of the effects of a column for adsorption of -2-microglobulin in patients with dialysis-related amyloidosis in Japan [J]. Ther Apher Dial. 2013.17(1): 40-47.
  • 8Lima JR. Salgado JV. Ferreira TC. et al. Cystatin c and inflammatory markers in kidney transplant recipients [J]. Rev Assoc Med Bras.2011.57(3) :347-352.
  • 9Angelidis C. Deftereos S. Giannopoulos G. et al. Cystatin c: an emerging biomarker in cardiovascular disease [J]. Curr Top Med Chem,2013.13(2) :164-179.
  • 10Maelns Naez JF, Ghsis Z,et al.Evaluation of oxidant- alltioxidant balance in oatients maintenance[J].Neohron ClinPract,2010,114(1):e67-73.

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部